Arnold S. Lippa, Ph.D. – Chief Scientific Officer, Executive Chairman of Board of Directors

Dr. Lippa has served as Executive Chairman since March, 2013 and Chief Scientific Officer since August, 2015. From March, 2013 until August, 2015 and from September, 2018 until May, 2020, he also served as President and Chief Executive Officer, respectively. He is a Senior Managing Director and founder of T Morgen Capital LLC through which he administers his family’s assets. T Morgen Capital LLC is a significant equity owner and managing member of Aurora Capital LLC (“Aurora”), a firm of which Mr. Margolis is the president and founder and which has served as a placement agent with respect to certain of the Company’s prior financings. Aurora was SEC registered and a  FINRA member firm until voluntarily withdrawing effective July 2021 and has been inactive in the securities and investment banking industry since April 2021. Dr. Lippa and Mr. Margolis founded and jointly manage, since 2004, Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life sciences fund management company and venture fund, respectively. Both entities are currently inactive. Dr. Lippa is a member of the Board of Directors of ContraVir Pharmaceuticals, Inc. since December 2015, where he is a member of the audit committee and the compensation committee. Dr. Lippa was co-founder of DOV Pharmaceutical, Inc., where he served as Chairman of the Board and Chief Executive Officer from its inception in 1995 through 2005 and which he took public in 2002.